Topoisomerase I-mediated DNA relaxation as a new target for the treatment of the autoimmune disease systemic lupus erythmatosus (SLE)

• Applicant: Privatdozent Dr. Steffen Frese
• Subject Area: Rheumatology
• Term: from 2016 to 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 317392477

• Final Report Year: 2022

Final Report Abstract

No abstract available

Publications

• Refractory mixed proliferative and membranous lupus nephritis treated with the topoisomerase I inhibitor irinotecan as add-on therapy. Scand J Rheumatol. May;51(3):237-240. (2022)
  Biesen R, Frese-Schaper M, Enghard P, Cheng Q, Hiepe F, Frese S
  (See online at https://doi.org/10.1080/03009742.2021.1980979)